Martin Shkreli investigated for running pharma company from jail

Mar 11, 2019

The infamous “Pharma Bro” is in the hot seat again — this time for allegedly involving himself in business dealings from prison with a contraband phone. 

Last week, the Wall Street Journal reported that Martin Shkreli has been discussing business deals and talking with executives from Pheonixus AG, the company he once led (which was previously named Turing Pharmaceuticals).

Shkreli became pharma’s most-loathed CEO in 2015 after Turing raised the price of Daraprim, which is used to prevent infections in HIV or transplant patients and treat toxoplasmosis, by 5,000 percent overnight. In the midst of the backlash, Shkreli was convicted of securities fraud and sentenced to seven years in a prison near Philadelphia. 

The Bureau of Prisons has now launched an investigation into reports of Shkreli conducting business on an illegal phone. If convicted, Shkreli could face another year in prison and a fine. 

Read the full WSJ report.

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments